MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer

Exclusion Criteria

• •Testosterone \>50 ng/dL
• •Use of corticosteroids and/or adrenal hormone inhibitors within 4 weeks of dosing
• •Use of PC-SPES within 4 weeks of dosing
• •Prior cytotoxic chemotherapy and/or radiation therapy within 6 weeks of dosing
• •Use of anti-androgen therapy (eg, flutamide, bicalutamide, nilutamide) within 6 weeks of dosing
• •Prior monoclonal antibody administration, including Prostascint®
• •Peripheral neuropathy of \> Grade 2, as defined by the NCI Common Toxicity Criteria for Adverse Events (NCI CTCAE)
• •History of CNS metastasis, including incompletely treated epidural disease
• •History of Hepatitis B or C
• •History of seizure disorder requiring active treatment and/or stroke
• •History of HIV infection
• •Platelet count \<100,000/mm3
• •Absolute neutrophil count (ANC) \<1,500/mm3
• •Hematocrit \<27 percent
• •Abnormal coagulation profile (elevated PT, and/or INR, PTT)
• •Serum creatinine \>2.0 mg/dL, or creatinine clearance \<60 mL/min if serum creatinine \>2.0 mg/dL
• •AST or ALT \>1.5 x ULN
• •Bilirubin (total) \>1.25 x ULN
• •Serum calcium \>12.5 mg/dL
• •Active serious infection not controlled by antibiotics
• •Active angina pectoris or NY Heart Association Class III-IV heart disease
• •Karnofsky Performance Status \<60%
• •Life expectancy \<6 months
• •Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or hematological organ systems that might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study.